Background-Ostial left anterior descending coronary artery (LAD) lesion has been regarded as a lesion subset unsuitable for coronary stenting. 
T he ostial left anterior descending coronary artery (LAD) lesion is an important target for coronary revascularization because its location subtends a large territory of myocardium. However, the ostial LAD lesion has been regarded as a lesion subset unsuitable for percutaneous coronary intervention (PCI) because of frequent atherosclerotic involvement of the distal left main coronary artery (LMCA) and because of concerns about compromising the circumflex coronary artery (LCX). Furthermore, restenosis rate after implantation of bare-metal stents (BMS) for ostial LAD lesions remains high, ranging from 26% to 33%. 1, 2 Although randomized controlled trials comparing drug-eluting stents (DES) with BMS demonstrated significant reduction in the rates of target lesion revascularization (TLR) with use of DES, ostial LAD lesions have been excluded from most of these trials. Despite increasingly frequent use of DES for the treatment of ostial LAD lesions, its long-term outcome has not been adequately evaluated. [3] [4] [5] The current analysis was conducted to evaluate 3-year clinical outcomes of patients who underwent sirolimus-eluting stent (SES) implantation for ostial LAD lesions in a large cohort of patients enrolled in the j-Cypher registry.
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Methods
Study Design and Patient Population
The study design for the j-Cypher registry was previously described. 6 In brief, the j-Cypher registry is a physician-directed, prospective, multicenter registry in Japan that enrolls consecutive patients undergoing SES implantation without any exclusion criteria (online-only Data Supplement Appendix A). For this study a center actively enrolled patients, technicians in the catheterization laboratory registered all the patients undergoing PCI in a screening log. When SES implantation was undertaken, the patient was invited to participate in the j-Cypher registry. Although data entry basically was left to the individual sites, the experienced clinical research coordinators (online-only Data Supplement Appendix B) in the data management center supported data entry when necessary. Logical inconsistencies were resolved by inquiries to the site investigators and audits against the original data sources. Follow-up data were obtained from hospital charts or by contacting patients and referring physicians at 30 days, 6 months, 1 year, and yearly thereafter. When death, myocardial infarction (MI), and stent thrombosis were reported, the events were adjudicated using the original source documents by a clinical events committee (online-only Data Supplement Appendix C). Adjudication of TLR events was left to the decision of the local investigators. The relevant review boards in all 37 participating centers approved the study protocol. Written informed consent was obtained from all patients enrolled.
The current prespecified subanalysis from the j-Cypher registry was intended to evaluate safety and efficacy of SES use in patients with ostial LAD lesions. Among 12 824 patients enrolled in the registry from August 2004 to November 2006, 6230 underwent PCI for proximal LAD disease. Excluding 380 patients in whom proximal LAD lesions were treated by modalities other than SES, the current study population consisted of 5850 patients whose proximal LAD lesions were treated exclusively with SES. Baseline characteristics and clinical outcomes were compared between 481 patients with ostial LAD lesions and 5369 patients with nonostial proximal LAD lesions. Subgroup analysis also was conducted in the 481 patients whose ostial LAD lesions were treated exclusively by SES. Baseline characteristics and clinical outcomes were compared between main branch stenting alone (1-stent approach, nϭ419) and both main and side branch stenting (2-stent approach, nϭ62). Furthermore, in patients who underwent the 1-stent approach, baseline characteristics and clinical outcomes were compared between crossover stenting across the LCX (crossover stenting, nϭ225) and stenting just at the ostium of LAD (ostial stenting, nϭ194) ( Figure 1 ).
Definitions
A lesion was defined as the area covered by single or multiple overlapping stents. When 2 stents were placed without overlap, these 2 areas were regarded as 2 separate lesions. Ostial lesion was defined as a narrowing located within 3 mm of the vessel origin in the least foreshortened angiographic projection. Those ostial LAD lesions with concomitant significant LMCA distal bifurcation stenosis were regarded as LMCA lesions and excluded from the current analysis. Proximal LAD was defined as the segment of LAD proximal to the first major septal branch. Techniques of stenting were prespecified and recorded in the case report forms during the index stent implantation procedures. Crossover stenting was defined as stent placement from distal LMCA to LAD across LCX, whereas ostial stenting was defined as a stenting strategy with an intention not to protrude the stent into LMCA. One-stent approach meant stenting of the LAD only (including crossover stenting and ostial stenting), and 2-stent approach denoted stenting of both ostial LAD and ostial LCX. Choice of the stenting strategies was left to the discretion of the operators.
The primary outcome measure for efficacy in the current analysis was defined as TLR for the index proximal LAD lesions. TLR was defined as either PCI or coronary artery bypass graft surgery due to restenosis or thrombosis of the target lesion that included the proximal and distal edge segments as well as the ostium of the side branches. The composite of death or MI was selected as the primary outcome measure for safety. Death was regarded as cardiac in origin unless obvious noncardiac causes could be identified. Any death during the index hospitalization was regarded as cardiac death. Sudden death was defined as unexplained death in previously stable patients. MI was adjudicated according to the definition in the Arterial Revascularization Therapy Study. 7 Stent thrombosis was defined according to the Academic Research Consortium definition. 8 
Statistical Analysis
Categorical variables are presented as counts and percentages and were compared with the 2 test. Continuous variables are expressed as meanϮSD, unless otherwise indicated. Continuous variables were compared with the Student t test or Wilcoxon rank sum test on the basis of their distribution. Cumulative incidences of events were estimated by the Kaplan-Meier method, and curves were compared with the log-rank test. A multivariable Cox proportional hazard model was developed to adjust the differences in baseline characteristics. Proportional hazard assumptions for variables were assessed on the plots of log (time) versus log [Ϫlog(survival)] stratified by the variables and were found justified. For the multivariable analysis, we first selected variables with PϽ0.1 in the univariate Cox models among 21 independent variables used in the previous report. 6 In the final multivariable model, we incorporated ostial LAD versus nonostial proximal LAD, or 1-stent approach versus 2-stent approach, and crossover stenting versus ostial stenting together with those independent variables with multivariable PϽ0.05. Covariates used in the final model for adjustment are shown in online-only Data Supplement Tables 1  through 6 . The results of the multivariable analysis are expressed as adjusted hazard ratios (HRs) and their 95% CIs.
Statistical analyses were conducted by 2 physicians (K.K., T.K.) and a statistician (T. Morimoto) with the use of JMP version 8.0 (SAS Institute Inc; Cary, NC) software. PϽ0.05 was considered statistically significant.
Results
Baseline Characteristics: Ostial LAD Versus Nonostial Proximal LAD
The baseline clinical characteristics were generally similar between the ostial LAD group and the nonostial proximal LAD group, although patients aged Ն80 years, those with prior MI, and statin users were more prevalent in the ostial LAD group (Table 1) . The baseline angiographic and procedural data were significantly different between the 2 groups ( Table 2 ). The ostial LAD group had larger vessel size, resulting in use of stents and balloons with bigger sizes. Directional coronary atherectomy before stenting, intravascular ultrasound, and postdilatation were more frequently used in the ostial LAD group. Minimal lumen diameter (MLD) postprocedure was significantly larger in the ostial LAD group. Data are presented as meanϮSD or n (%). Data were missing for de novo lesion in 1 lesion, in-stent restenosis in 1 lesion, chronic total occlusion in 14 lesions, lesion length Ն30 mm in 68 lesions, reference vessel diameter pre Ͻ2.5 mm in 63 lesions, use of intravascular ultrasound in 17 lesions, direct stenting in 7 lesions, postdilatation in 9 lesions, maximum inflation pressure in 43 lesions, lesion length in 68 lesions, reference vessel diameter pre in 63 lesions, minimal lumen diameter pre in 63 lesions, diameter stenosis pre in 22 lesions, reference vessel diameter post in 53 lesions, minimal lumen diameter post in 53 lesions, and diameter stenosis post in 23 lesions. LAD indicates left anterior descending coronary artery.
Clinical Outcomes: Ostial LAD Versus Nonostial Proximal LAD
The follow-up interval in surviving patients was significantly longer in those with ostial LAD lesions (median, 995 days; interquartile range, 732 to 1095 days) than in those with nonostial proximal LAD lesions (median, 904 days; interquartile range, 730 to 1095 days; Pϭ0.02). Follow-up at 1 year was completed in 97% of patients.
Cumulative incidence of TLR in the ostial LAD group was not different from that in the nonostial proximal LAD group (9.4% versus 9.7%, Pϭ0.98) (Figure 2A , Table 3 ). Adjusted HR of ostial LAD versus nonostial proximal LAD for TLR was 0.99 (95% CI, 0.7 to 1.36; Pϭ0.94). Similarly, cumulative incidences of death or MI were not significantly different between the 2 groups (10.7% versus 11.4%, Pϭ0.82) ( Figure  2B ). Adjusted HR of ostial LAD versus nonostial proximal LAD for death or MI was 1.05 (95% CI, 0.76 to 1.4; Pϭ0.77).
Baseline Characteristics: One-Stent Versus Two-Stent Approach
The baseline clinical characteristics were generally similar between the 1-stent approach group and the 2-stent approach group, although patients aged Ն80 years were more prevalent in the 2-stent approach group (online-only Data Supplement Table 7 ). The baseline procedural and angiographic data were significantly different between the 2 groups. The crossoverstenting approach and final kissing balloon technique were more frequently used in the 2-stent approach group. The number and length of stents were greater in the 2-stent approach group. Obviously, the prevalence of significant narrowing at the ostium of LCX was markedly higher in the 2-stent approach group. Reference diameter and MLD of LCX preprocedure were significantly smaller in the 2-stent approach group than in the 1-stent approach group. Despite these differences in procedural and angiographic characteristics, postprocedural MLD in the main branch did not differ between the 2 groups. Final MLD of LCX was significantly larger in the 2-stent approach group than in the 1-stent approach group (online-only Data Supplement Table 8 ).
Clinical Outcomes: One-Stent Versus Two-Stent Approach
Cumulative incidence of TLR in the 2-stent group was significantly higher than that in the 1-stent group (28.1% versus 6.6%, PϽ0.0001) ( Figure 3A , Table 3 ). The adjusted HR of the 2-stent approach versus 1-stent approach for TLR was 4.65 (95% CI, 2.32 to 9.25; PϽ0.0001). Cumulative incidences of stroke, coronary artery bypass graft, and any coronary revascularization also were significantly higher in the 2-stent group than those in the 1-stent group. However, cumulative incidences of death or MI were not significantly different between the 2 groups (16.8% versus 9.8%, Pϭ0.37) ( Figure 3B , Table 4 ). Adjusted HR of the 2-stent approach versus the 1-stent approach for death or MI was 1.15 (95% CI, 0.49 to 2.41; Pϭ0.73).
Baseline Characteristics: Crossover Stenting Versus Ostial Stenting
Although the baseline clinical characteristics were generally similar between the ostial-stenting group and the crossoverstenting group, the latter included more male patients and patients with prior heart failure (online-only Data Supplement Table 9 ). The baseline procedural and angiographic data were significantly different between the 2 groups. Final kissing balloon technique was more frequently used in the crossoverstenting group, reflecting greater prevalence of significant narrowing at the ostium of LCX. Although the crossover- stenting group had larger stent size, larger maximum balloon size, and longer stent length, postprocedural MLD in the main branch did not differ between the 2 groups. Final MLD of LCX was significantly smaller in the crossover-stenting group than in the ostial-stenting group (online-only Data Supplement Table 10 ).
Clinical Outcomes: Crossover Stenting Versus Ostial Stenting
Cumulative incidences of TLR were not significantly different between the crossover-stenting group and the ostialstenting group (5.4% versus 7.9%, Pϭ0.81) ( Figure 4A , Table 5 ). Adjusted HR of crossover stenting versus ostial stenting for TLR was 0.77 (95% CI, 0.33 to 1.82; Pϭ0.55). Similarly, cumulative incidences of death or MI were not significantly different between the 2 groups (12.2% versus 7.0%, Pϭ0.07) ( Figure 4B , Table 5 ). Adjusted HR of crossover stenting versus ostial stenting for death or MI was 1.54 (95% CI, 0.78 to 3.2; Pϭ0.22). Although the crude incidence of all-cause death was significantly higher in the crossover-stenting group (12.2% versus 4.5%, Pϭ0.01), the difference was no longer significant after adjusting for confounders (adjusted HR, 2.04; 95% CI, 0.94 to 4.93; Pϭ0.07) ( Table 5 ).
Discussion
The main findings of the current analysis in the largest-ever reported series of patients undergoing SES implantation for ostial LAD lesions to our knowledge are as follows: (1) In terms of both safety and efficacy, 3-year outcomes of PCI using SES for ostial LAD lesions were comparable to those for nonostial proximal LAD lesions, (2) the 2-stent approach compared with the 1-stent approach was associated with a significantly higher rate of TLR, and (3) clinical outcomes after crossover stenting with the 1-stent approach for ostial LAD lesions were similar to those after ostial stenting.
Drawbacks of BMS Implantation for Ostial LAD Lesions
The ostial LAD lesion historically has been regarded as a lesion subset unsuitable for PCI using coronary stents. One of the shortcomings of coronary stenting for ostial LAD lesions is the potential for compromising the LCX either by plaque shifting or by pinching the LCX ostium. When the ostium of LCX already has been significantly narrowed before the procedure; thus, stenting of both LAD and LCX might be the only way to optimize the final angiographic result. However, in the era of BMS, stenting both main and side branches is considered to be contraindicated in treating bifurcation lesions because of an unacceptably high restenosis rate. 9 Additionally, ostial LAD lesions often are contiguous with distal LMCA disease, even if the LMCA lesions are not angiographically significant. Progression of the LMCA lesions subsequent to the injuries during stent implantation procedure have been another potential concern related to coronary stenting for ostial LAD lesions. Furthermore, it is technically demanding to place a stent just at the ostium of the LAD without missing the adequate coverage of the lesion and without excessive protrusion into the distal LMCA bifurcation. Therefore, surgical revascularization could still be considered in patients with ostial LAD lesions, even if they have single-vessel coronary artery disease.
Outcomes of DES Implantation for Ostial LAD Lesions
Despite increasingly frequent use of DES for the treatment of ostial LAD lesions, there are only a few small previous studies evaluating the outcome of DES implantation for ostial LAD lesions. Seung et al 3 compared the clinical outcome of 68 consecutive patients undergoing SES implantation with that of 77 historic control patients undergoing BMS implantation. The rate of TLR at 1 year was reported to be less frequent in the SES group than in the BMS group (0% versus 17%, PϽ0.001). Tsagalou et al 4 compared the clinical out- come of 43 consecutive patients undergoing DES implantation with that of 43 historic control patients undergoing BMS implantation. The rate of TLR at 9 months was reported to be less frequent in the DES group than in the BMS group (7% versus 25.6%, PϽ0.001). The current analysis evaluating a larger number of patients clearly demonstrated that the rate of TLR at 3 years after SES implantation in patients with ostial LAD lesions was comparable to that in patients with nonostial proximal LAD lesions in whom PCI using DES was regarded as the standard of care. The incidences of death or MI were also similar between patients with ostial LAD lesions and those with nonostial proximal LAD lesions, suggesting safety of PCI using SES for the ostial LAD lesions.
Stent Implantation Techniques for Ostial LAD Lesions
A relatively high restenosis rate in ostial lesions might be related to incomplete lesion coverage due to the technical difficulties in stent positioning in this lesion location. Encouraged by the favorable outcomes after unprotected LMCA stenting with DES, the crossover-stenting technique has emerged as a new stenting strategy for the ostial LAD lesions. 3, 5, 10, 11 In the current analysis, crossover stenting was adopted in 56% of patients undergoing SES implantation for ostial LAD lesions. Cumulative incidences of TLR and death or MI after crossover stenting were not different from those after ostial stenting, suggesting safety and efficacy of crossover stenting in selected anatomic situations. The crossoverstenting technique that enables easier stent positioning and full coverage of the lesion seems to be particularly relevant in treating those ostial LAD lesions with concomitant distal LMCA disease.
In the current analysis, the rate of TLR in patients who underwent stenting of both main and side branches was unacceptably high, as was reported for unprotected LMCA stenting. 12 Although we could not address the safety issues of the 2-stent approach because of the small sample size, it would be too premature to promote PCI using DES in patients in whom the 2-stent approach is likely to be required.
Study Limitations
There are several important limitations in this study. First, we do not have the control group of patients treated by coronary artery bypass graft. However, a single-digit TLR rate at 3 years after PCI seems to be clinically acceptable, even if we do not have the surgical control patients. Second, the choices regarding treatment strategies for the ostial LAD lesions were left to discretion of the operators and were not based on randomized assignment. Treatment strategies were chosen according to the various anatomic features of the ostial LAD lesions. Therefore, the comparison between crossover stenting and ostial stenting may not be clinically relevant. Additionally, we could not address the issue of the optimal 2-stent technique because of the small number of patients treated with the 2-stent approach. Third, angiograms were not analyzed by a core angiographic laboratory; therefore, the adjudication of ostial lesion was left to the judgment of the local investigators. Fourth, we could not address the issue of lesion progression of LMCA and ostial LCX because we did not evaluate the follow-up angiograms. Fifth, because we could not fully monitor the study patients, there is potential for underreporting of adverse events with potential for bias. Finally, although this is the largest series of patients undergoing SES implantation for ostial LAD lesions, the study is obviously underpowered to evaluate potential small differences in clinical outcomes. Furthermore, small numbers of events severely limit our ability to make adequate statistical adjustment by multivariable analysis; therefore, the multivariable findings are exploratory because of the small sample size.
Conclusions
In terms of both safety and efficacy, 3-year outcomes of PCI using SES for ostial LAD lesions were comparable to those for nonostial proximal LAD lesions. Crossover stenting across the LCX with a 1-stent approach might be a reasonable option in treating ostial LAD lesions. The 2-stent approach for bifurcation was associated with a markedly higher rate of TLR than the 1-stent approach.
